<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> is associated with an increased risk of <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>A major contributing factor to this risk is the abnormal <z:chebi fb="23" ids="18059">lipid</z:chebi> profile known as <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidaemia</z:e>, which is characterized by <z:hpo ids='HP_0003233'>low HDL cholesterol</z:hpo> (<z:chebi fb="0" ids="47775">HDL-C</z:chebi>), raised <z:chebi fb="4" ids="17855">triglycerides</z:chebi> (TGs) and a predominance of small, dense <z:chebi fb="1" ids="47774">LDL cholesterol</z:chebi> (<z:chebi fb="0" ids="47774">LDL-C</z:chebi>) particles </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="0" ids="35664">Statins</z:chebi> are now widely used first-line in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> due to their proven efficacy in reducing <z:chebi fb="0" ids="47774">LDL-C</z:chebi> and cardiovascular risk </plain></SENT>
<SENT sid="3" pm="."><plain>However, despite the use of <z:chebi fb="0" ids="35664">statins</z:chebi>, the absolute risk of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e> in patients remains elevated, highlighting the need to target <z:hpo ids='HP_0000001'>all</z:hpo> aspects of the diabetic <z:chebi fb="23" ids="18059">lipid</z:chebi> profile such as raised TGs or low <z:chebi fb="0" ids="47775">HDL-C</z:chebi> levels </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0000855'>Insulin resistance</z:hpo> is thought to be central in the pathogenesis of diabetic <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidaemia</z:e>; therefore, improving insulin sensitivity with a thiazolidinedione offers an attractive treatment option </plain></SENT>
<SENT sid="5" pm="."><plain>Indeed, <z:chebi fb="0" ids="8228">pioglitazone</z:chebi>, a member of the peroxisome proliferator-activated receptor-gamma family, has been shown in clinical trials to improve both blood <z:chebi fb="105" ids="17234">glucose</z:chebi> levels and the <z:chebi fb="23" ids="18059">lipid</z:chebi> profile when used either as monotherapy or in combination with other oral <z:chebi fb="0" ids="35526">antidiabetic</z:chebi> agents </plain></SENT>
<SENT sid="6" pm="."><plain>In the monotherapy setting, <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> has been associated with greater decreases in TGs and increases in <z:chebi fb="0" ids="47775">HDL-C</z:chebi> when compared with <z:chebi fb="0" ids="5441">glibenclamide</z:chebi> or <z:chebi fb="0" ids="6801">metformin</z:chebi> </plain></SENT>
<SENT sid="7" pm="."><plain>Studies investigating the effects of <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> add-on therapy to either <z:chebi fb="0" ids="6801">metformin</z:chebi> or sulphonylurea treatments have shown sustained improvements in serum levels of TGs and <z:chebi fb="0" ids="47775">HDL-C</z:chebi> and favourable effects on <z:chebi fb="0" ids="47774">LDL-C</z:chebi> particle size </plain></SENT>
<SENT sid="8" pm="."><plain>In comparison with <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi>, <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> has different and potentially favourable effects on plasma <z:chebi fb="23" ids="18059">lipids</z:chebi> </plain></SENT>
<SENT sid="9" pm="."><plain>The recent PROspective pioglitAzone Clinical Trial In macroVascular Events study has given weight to the hypothesis that the beneficial metabolic effects of <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> may be associated with reductions in cardiovascular risk in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
</text></document>